Table 1 Patient characteristics and univariate analysis between the recurrent group and the progression-free group
All | Progression-free group | Recurrent group | P | ||
|---|---|---|---|---|---|
n = 97 | n = 40 | n = 57 | |||
Age (years) | 51.1 ± 7.8 | 52.0 ± 7.9 | 50.5 ± 7.8 | 0.349 | |
BMI | 22.4 ± 3.0 | 22.7 ± 3.3 | 22.1 ± 2.8 | 0.292 | |
Family histroy | None | 72 (74.2%) | 30 (75.0%) | 42 (73.7%) | 0.793 |
Other cancer | 21 (21.6%) | 9 (22.5%) | 12 (21.1%) | ||
Ovarian cancer | 4 (4.1%) | 1 (2.5%) | 3 (5.3%) | ||
Serum CA-125 level (U/ml) | Pretreatment | 1374.9 ± 1653.8 | 1060.7 ± 1036.5 | 1595.9 ± 1955.8 | 0.093 |
Postprimary treatment | 8.8 ± 5.1 | 6.3 ± 2.2 | 10.5 ± 5.7 | 0.000 | |
Serum HE-4 level after primary treatment (pmol/l) | 60.9 ± 20.0 | 59.0 ± 20.1 | 62.1 ± 20.1 | 0.501 | |
Presence of pleural fluid (n, %) | 21 (21.6%) | 8 (20.0%) | 13 (22.8%) | 0.806 | |
Presence of ascitic fluid ≥ 1000 ml (n, %) | 55 (56.7%) | 26 (65.0%) | 29 (50.9%) | 0.213 | |
Stage (FIGO) (n, %) | IIB | 7 (7.2%) | 4 (10.0%) | 3 (5.3%) | 0.562 |
IIIA | 6 (6.2%) | 4 (10.0%) | 2 (3.5%) | ||
IIIB | 8 (8.2%) | 3 (7.5%) | 5 (8.8%) | ||
IIIC | 72 (74.2%) | 28 (70.0%) | 44 (77.2%) | ||
IVA | 4 (4.1%) | 1 (2.5%) | 3 (5.3%) | ||
Confirmaiton of diagnosis (n, %) | Preoperatively | 51 (52.6%) | 17 (42.5%) | 34 (59.6%) | 0.208 |
Intraoperatively | 43 (44.3%) | 22 (55.0%) | 21 (36.8%) | ||
After incomplete surgery | 3 (3.1%) | 1 (2.5%) | 2 (3.5%) | ||
Primary surgery (n, %) | IDS with NACT | 53 (54.6%) | 16 (40.0%) | 37 (64.9%) | 0.022 |
PDS | 44 (45.4%) | 24 (60.0%) | 20 (35.1%) | ||
Optimal cytoduction (n, %) | R0 | 61 (62.9%) | 24 (60.0%) | 37 (64.9%) | 0.673 |
R1 | 36 (37.1%) | 16 (40.0%) | 20 (35.1%) | ||
Areas with residual disease (n, %) | Pelvis | 13 (13.4%) | 5 (12.5%) | 8 (14.0%) | 0.284 |
Upper obdomen | 6 (6.7%) | 1 (2.5%) | 5 (8.8%) | ||
Scattered milia | 17 (17.5%) | 10 (25.0%) | 7 (12.3%) | ||
Systematic lymphadenectomy (n, %) | 74 (76.3%) | 33 (82.5%) | 41 (71.9%) | 0.332 | |
Lymph node metastasis (n, %) | Not detected | 55 (56.7%) | 24 (60.0%) | 31 (54.4%) | 0.662 |
Spread to pelvic lymph nodes | 24 (24.7%) | 8 (20.0%) | 16 (28.1%) | ||
Spread to para-aortic lymph nodes | 18 (18.6%) | 8 (20.0%) | 10 (17.5%) | ||
Postoperative chemotherapy | Number of cycles | 7.2 ± 1.2 | 7.2 ± 0.9 | 7.2 ± 1.4 | 0.968 |
Paclitaxel/cisplatin (n, %) | 38 (39.2%) | 15 (37.5%) | 23 (40.1%) | 0.501 | |
Paclitaxel/carboplatin (n, %) | 29 (29.9%) | 14 (35.0%) | 15 (26.3%) | ||
Alternately (n, %) | 30 (30.9%) | 11 (30.0%) | 19 (33.3%) | ||
Postremission therapy (n, %) | None | 71 (73.2%) | 27 (67.5%) | 44 (77.2%) | 0.111 |
Chemotherapy | 22 (22.7%) | 13 (32.5%) | 9 (15.8%) | ||
Bevacizumab | 2 (2.1%) | 0 (0%) | 2 (3.5%) | ||
Pazopanib | 2 (2.1%) | 0 (0%) | 2 (3.5%) | ||